Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents

Completed · Phase 2

Conditions studied: Prevention of Meningococcal Disease

In brief

The purpose of this study is to evaluate the safety and immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in comparison to licensed meningococcal polysaccharide vaccine administered to healthy adolescents ages 11 to 17 years.

Key facts

Study ID

NCT00262041

Run by

Novartis Vaccines

People needed

524

Starts

2004-10-01

Expected to finish

2006-03-01

Last updated by the study team

2018-06-28

Who can join

Age: 11 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Healthy adolescents between and including 11-17 years of age, who provide written informed consent

You may not qualify if…

• Subjects with a previous or suspected disease caused by N. meningitidis; or previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s); Any serious acute, chronic or progressive disease

Where it is running

• Study site — Rochester, Minnesota, United States
• Study site — Pittsburgh, Pennsylvania, United States
• Study site — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.